1. India Stocks

  2. •

    Finance

  3. •

    Real estate development
Astal Laboratories Ltd

Astal Laboratories Ltd

BBSE:ASTALLTD
63.75
INR
-4.10
(-6.04%)
5.65EPS
14.82P/E
3.85BMarket Cap
Astal Laboratories Ltd
BSE:ASTALLTD
(Bombay Stock Exchange)

Recent

price

63.75

P/E

ratio

14.82

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
- -
- -
2.73
- -
- -
- -
- -
- -
- -
- -
- -
- -
8.63
46.82
65.34
59.25
90.54
Revenue per Share
0.06
-0.21
-0.58
0.23
0.46
0.02
0.01
-0.02
-0.21
-0.07
0.02
-0.04
0.04
1.55
9.08
3.48
6.04
Basic EPS, GAAP
-0.53
-2.52
-2.06
-2.07
-0.85
-0.83
-0.76
-0.76
-0.76
-0.5
-0.47
-0.63
-3.62
-22.76
-18.61
-4.59
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
12.87
13.15
12.58
12.81
13.27
13.29
13.3
13.29
13.08
13.01
13.02
12.99
13.03
23.74
36.62
79.06
- -
Book Value per Share
12.87
13.15
12.58
12.81
13.27
13.29
13.3
13.29
13.08
13.01
13.02
12.99
13.03
23.74
36.62
30.93
- -
Tangible Book Value per Share
4
4
4
4
4
4
4
4
4
4
4
4
4
5
10
42
26
Basic Weighted Avg Shares
- -
- -
11
- -
- -
- -
- -
- -
- -
- -
- -
- -
34
236
642
2,501
2,316
Sales/Revenue/Turnover
- -
- -
-9.75
- -
- -
- -
- -
- -
- -
- -
- -
- -
-4.27
4.59
19.54
7.81
8.82
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
10
14
Depreciation Expense
- -
-1
-2
1
2
- -
- -
- -
-1
- -
- -
- -
- -
8
89
147
154
Net Income, GAAP
- -
- -
246.67
21.87
- -
56.61
51.47
- -
- -
- -
25.77
- -
48.6
27.78
25.48
17.04
16.15
Effective Tax Rate (%)
- -
- -
-21.14
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.48
3.32
13.9
5.88
6.67
Profit Margin (%)
33
43
46
52
52
52
51
51
50
50
51
- -
14
137
189
783
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
5
193
- -
LT Debt
51
52
50
51
53
53
53
53
52
52
52
52
52
233
360
3,338
- -
Total Equity
- -
- -
-4.49
1.82
- -
0.15
0.1
- -
- -
- -
-2.8
- -
-1.46
5.36
24.45
7.29
- -
Return on Invested Capital (%)
- -
- -
-4.49
1.82
- -
0.15
0.1
- -
- -
- -
0.12
- -
0.32
5.5
25.74
7.45
- -
Return on Capital (%)
0.44
-1.58
-4.49
1.82
3.56
0.15
0.1
-0.12
-1.57
-0.54
0.12
-0.33
0.32
5.5
30.08
7.96
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
306
- -
LT Borrowings
- -
186
- -
LT Finance Leases
- -
6
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
42
43
Market Capitalization
935
2,759
3,854

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,432
- -
Cash, Cash Equivalents & STI
- -
10
- -
Accounts Receivable, Net
- -
1,569
- -
Inventories
- -
675
- -
Total Current Liabilities
- -
1,648
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
306
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
123.03%
246.46%
827.24%
Free Cash Flow
122.77%
255.25%
5.99%
Net Income, GAAP
589.99%
1,041.41%
64.81%
Sales/Revenue/Turnover
- -
- -
289.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
131
132
145
235
642
2026
253
375
522
409
2,501
2027
1,009
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.72
2.04
2.53
2.8
9.08
2026
2.13
2.39
2.19
0.29
3.48
2027
2.19
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
DLF Limited (NSE:DLF)
Opendoor Technologies Inc (NASDAQ:OPEN)
Samolet (MOEX:SMLT)
Alarko Holding A.S. (BIST:ALARK)
Godrej Properties Limited (NSE:GODREJPROP)
Lodha Developers Ltd. (NSE:LODHA)
Business
Astal Laboratories Ltd is an India-based pharmaceutical company engaged in the research, development, manufacturing, and commercial distribution of active pharmaceutical ingredients (APIs), finished dosage formulations, and specialty healthcare products. The company operates across primary healthcare and therapeutic segments, providing a comprehensive product and service portfolio that includes oral solid formulations such as immediate-release, sustained-release, and enteric-coated tablets as well as hard and soft gelatin capsules; oral liquid preparations comprising pharmaceutical syrups, suspensions, oral drops, and pediatric elixirs; sterile dosage forms including small-volume parenterals, lyophilized injectables, and intravenous solutions; topical dermatological products including therapeutic ointments, medicinal creams, and anti-fungal gels; active pharmaceutical ingredients and advanced intermediate compounds targeting cardiovascular, anti-infective, gastrointestinal, central nervous system, and analgesic therapeutic categories; and over-the-counter dietary supplements including multivitamins, mineral complexes, and nutraceutical formulations. In addition to proprietary product lines, the company provides end-to-end contract development and manufacturing organization (CDMO) services, analytical testing, stability studies, formulation development, and private-label manufacturing for institutional clients and third-party pharmaceutical enterprises. In recent developments, Astal Laboratories Ltd has upgraded and expanded its primary manufacturing facilities to align with modern Current Good Manufacturing Practice (cGMP) standards, launched a new pipeline of generic fixed-dose combination therapies focused on chronic disease management, entered into strategic distribution alliances to expand its presence across emerging markets in Southeast Asia, the Middle East, and Africa, and broadened its contract manufacturing agreements with domestic healthcare brands to increase capacity utilization. Founded in 2004 and headquartered in Mumbai, India, Astal Laboratories Ltd distributes its products to hospital networks, government health agencies, retail pharmacy chains, and international commercial partners.